Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28988646

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2017 Nov
First author
Tawbi HA

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Nov;18(11):1430-1431. doi: 10.1016/S1470-2045(17)30685-X.
    note
    Source null
    related pmid
    28988645
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2017 Dec;18(12):e711. doi: 10.1016/S1470-2045(17)30864-1.
    note
    Source null
    related pmid
    29208435
    relationship
    Erratum in
  3. citation
    Lancet Oncol. 2018 Jan;19(1):e6. doi: 10.1016/S1470-2045(17)30921-X.
    note
    Source null
    related pmid
    29304365
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2018 Jan;19(1):e7. doi: 10.1016/S1470-2045(17)30922-1.
    note
    Source null
    related pmid
    29304367
    relationship
    Comment in
  5. citation
    Lancet Oncol. 2018 Jan;19(1):e8. doi: 10.1016/S1470-2045(17)30926-9.
    note
    Source null
    related pmid
    29304368
    relationship
    Erratum in

Authors and identifiers

  1. name
    Tawbi HA
    type
    Author
  2. name
    Burgess M
    type
    Author
  3. name
    Bolejack V
    type
    Author
  4. name
    Van Tine BA
    type
    Author
  5. name
    Schuetze SM
    type
    Author
  6. name
    Hu J
    type
    Author
  7. name
    D'Angelo S
    type
    Author
  8. name
    Attia S
    type
    Author
  9. name
    Riedel RF
    type
    Author
  10. name
    Priebat DA
    type
    Author
  11. name
    Movva S
    type
    Author
  12. name
    Davis LE
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Tawbi HA
    type
    Author
  2. name
    Burgess M
    type
    Author
  3. name
    Bolejack V
    type
    Author
  4. name
    Van Tine BA
    type
    Author
  5. name
    Schuetze SM
    type
    Author
  6. name
    Hu J
    type
    Author
  7. name
    D'Angelo S
    type
    Author
  8. name
    Attia S
    type
    Author
  9. name
    Riedel RF
    type
    Author
  10. name
    Priebat DA
    type
    Author
  11. name
    Movva S
    type
    Author
  12. name
    Davis LE
    type
    Author
bibliography ids
  1. nci-bib-fb872b827468f3de010ceca9
book metadata
content sha256
37a0aa612f8dea8d1e92e04acbc182a62dfe750d098404562c1a78c0e678f3f3
document type
citation
dois
  1. 10.1016/S1470-2045(17)30624-1
electronic publication date
display
2017 Oct 4
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28988646
immutable id
pubmed:28988646@37a0aa612f8dea8d1e92e04acbc182a62dfe750d098404562c1a78c0e678f3f3
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
11
name
The Lancet. Oncology
nlm unique id
100957246
pages
1493-1501
volume
18
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Nov;18(11):1430-1431. doi: 10.1016/S1470-2045(17)30685-X.
    note
    Source null
    related pmid
    28988645
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2017 Dec;18(12):e711. doi: 10.1016/S1470-2045(17)30864-1.
    note
    Source null
    related pmid
    29208435
    relationship
    Erratum in
  3. citation
    Lancet Oncol. 2018 Jan;19(1):e6. doi: 10.1016/S1470-2045(17)30921-X.
    note
    Source null
    related pmid
    29304365
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2018 Jan;19(1):e7. doi: 10.1016/S1470-2045(17)30922-1.
    note
    Source null
    related pmid
    29304367
    relationship
    Comment in
  5. citation
    Lancet Oncol. 2018 Jan;19(1):e8. doi: 10.1016/S1470-2045(17)30926-9.
    note
    Source null
    related pmid
    29304368
    relationship
    Erratum in
outcomes validated
false
pmid
28988646
provenance
batch id
fb25b16edcb1373b70c1
provider
NCBI PubMed ESummary
record sha256
c5efe362e0e8cabe0136e3ae086190e74935313dfce5d92a4bf613c4476648d0
response sha256
182c99bf1974b58308315b66aa28d31c61e8fc31cf3de4cadb0340a4f6734c52
retrieved at
2026-09-09T23:47:28.490065+00:00
publication date
display
2017 Nov
precision
month
year
2017
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28988646/
title
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.

Preserved source evidence · Not medical advice